241 related articles for article (PubMed ID: 2575380)
1. Highly specific inhibition of human immunodeficiency virus type 1 by a novel 6-substituted acyclouridine derivative.
Baba M; Tanaka H; De Clercq E; Pauwels R; Balzarini J; Schols D; Nakashima H; Perno CF; Walker RT; Miyasaka T
Biochem Biophys Res Commun; 1989 Dec; 165(3):1375-81. PubMed ID: 2575380
[TBL] [Abstract][Full Text] [Related]
2. Anti-human immunodeficiency virus type 1 activities and pharmacokinetics of novel 6-substituted acyclouridine derivatives.
Baba M; De Clercq E; Iida S; Tanaka H; Nitta I; Ubasawa M; Takashima H; Sekiya K; Umezu K; Nakashima H
Antimicrob Agents Chemother; 1990 Dec; 34(12):2358-63. PubMed ID: 2088190
[TBL] [Abstract][Full Text] [Related]
3. Highly potent and selective inhibition of human immunodeficiency virus type 1 by a novel series of 6-substituted acyclouridine derivatives.
Baba M; De Clercq E; Tanaka H; Ubasawa M; Takashima H; Sekiya K; Nitta I; Umezu K; Walker RT; Mori S
Mol Pharmacol; 1991 Jun; 39(6):805-10. PubMed ID: 1711148
[TBL] [Abstract][Full Text] [Related]
4. Synergistic inhibition of human immunodeficiency virus type 1 (HIV-1) replication in vitro by 1-[(2-hydroxyethoxy)methyl]-6-phenylthiothymine (HEPT) and recombinant alpha interferon.
Ito M; Baba M; Shigeta S; De Clercq E; Walker RT; Tanaka H; Miyasaka T
Antiviral Res; 1991 May; 15(4):323-30. PubMed ID: 1683214
[TBL] [Abstract][Full Text] [Related]
5. Synergistic inhibition of human immunodeficiency virus type 1 replication by 5-ethyl-1-ethoxymethyl-6-(phenylthio)uracil (E-EPU) and azidothymidine in vitro.
Baba M; Ito M; Shigeta S; Tanaka H; Miyasaka T; Ubasawa M; Umezu K; Walker RT; De Clercq E
Antimicrob Agents Chemother; 1991 Jul; 35(7):1430-3. PubMed ID: 1929304
[TBL] [Abstract][Full Text] [Related]
6. Synthesis and anti-HIV activity of 2-, 3-, and 4-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).
Tanaka H; Baba M; Ubasawa M; Takashima H; Sekiya K; Nitta I; Shigeta S; Walker RT; De Clercq E; Miyasaka T
J Med Chem; 1991 Apr; 34(4):1394-9. PubMed ID: 2016715
[TBL] [Abstract][Full Text] [Related]
7. Structure-activity relationships of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine analogues: effect of substitutions at the C-6 phenyl ring and at the C-5 position on anti-HIV-1 activity.
Tanaka H; Takashima H; Ubasawa M; Sekiya K; Nitta I; Baba M; Shigeta S; Walker RT; De Clercq E; Miyasaka T
J Med Chem; 1992 Jan; 35(2):337-45. PubMed ID: 1732552
[TBL] [Abstract][Full Text] [Related]
8. A new class of HIV-1-specific 6-substituted acyclouridine derivatives: synthesis and anti-HIV-1 activity of 5- or 6-substituted analogues of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT).
Tanaka H; Baba M; Hayakawa H; Sakamaki T; Miyasaka T; Ubasawa M; Takashima H; Sekiya K; Nitta I; Shigeta S
J Med Chem; 1991 Jan; 34(1):349-57. PubMed ID: 1992136
[TBL] [Abstract][Full Text] [Related]
9. Resistance to 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives is generated by mutations at multiple sites in the HIV-1 reverse transcriptase.
Buckheit RW; Fliakas-Boltz V; Yeagy-Bargo S; Weislow O; Mayers DL; Boyer PL; Hughes SH; Pan BC; Chu SH; Bader JP
Virology; 1995 Jun; 210(1):186-93. PubMed ID: 7540784
[TBL] [Abstract][Full Text] [Related]
10. Anti-HIV-1 activity of antiviral compounds, as quantitated by a focal immunoassay in CD4+ HeLa cells and a plaque assay in MT-4 cells.
Nakashima H; Balzarini J; Pauwels R; Schols D; Desmyter J; De Clercq E
J Virol Methods; 1990 Aug; 29(2):197-208. PubMed ID: 1980126
[TBL] [Abstract][Full Text] [Related]
11. Kinetics of inhibition of endogenous human immunodeficiency virus type 1 reverse transcription by 2',3'-dideoxynucleoside 5'-triphosphate, tetrahydroimidazo-[4,5,1-jk][1,4]-benzodiazepin-2(1H)-thion e, and 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine derivatives.
Debyser Z; Vandamme AM; Pauwels R; Baba M; Desmyter J; De Clercq E
J Biol Chem; 1992 Jun; 267(17):11769-76. PubMed ID: 1376311
[TBL] [Abstract][Full Text] [Related]
12. Potent and selective inhibition of human immunodeficiency virus type 1 (HIV-1) by 5-ethyl-6-phenylthiouracil derivatives through their interaction with the HIV-1 reverse transcriptase.
Baba M; De Clercq E; Tanaka H; Ubasawa M; Takashima H; Sekiya K; Nitta I; Umezu K; Nakashima H; Mori S
Proc Natl Acad Sci U S A; 1991 Mar; 88(6):2356-60. PubMed ID: 1706522
[TBL] [Abstract][Full Text] [Related]
13. Effect of human serum on the in vitro anti-HIV-1 activity of 1-[(2-hydroxyethoxy)methyl]-6-(phenylthio)thymine (HEPT) derivatives as related to their lipophilicity and serum protein binding.
Baba M; Yuasa S; Niwa T; Yamamoto M; Yabuuchi S; Takashima H; Ubasawa M; Tanaka H; Miyasaka T; Walker RT
Biochem Pharmacol; 1993 Jun; 45(12):2507-12. PubMed ID: 8328988
[TBL] [Abstract][Full Text] [Related]
14. Potent and selective inhibition of HIV-1 replication in vitro by a novel series of TIBO derivatives.
Pauwels R; Andries K; Desmyter J; Schols D; Kukla MJ; Breslin HJ; Raeymaeckers A; Van Gelder J; Woestenborghs R; Heykants J
Nature; 1990 Feb; 343(6257):470-4. PubMed ID: 1689015
[TBL] [Abstract][Full Text] [Related]
15. Potent and selective inhibition of human immunodeficiency virus (HIV)-1 and HIV-2 replication by a class of bicyclams interacting with a viral uncoating event.
De Clercq E; Yamamoto N; Pauwels R; Baba M; Schols D; Nakashima H; Balzarini J; Debyser Z; Murrer BA; Schwartz D
Proc Natl Acad Sci U S A; 1992 Jun; 89(12):5286-90. PubMed ID: 1608936
[TBL] [Abstract][Full Text] [Related]
16. (-)-2'-deoxy-3'-thiacytidine is a potent, highly selective inhibitor of human immunodeficiency virus type 1 and type 2 replication in vitro.
Coates JA; Cammack N; Jenkinson HJ; Jowett AJ; Jowett MI; Pearson BA; Penn CR; Rouse PL; Viner KC; Cameron JM
Antimicrob Agents Chemother; 1992 Apr; 36(4):733-9. PubMed ID: 1380229
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of human immunodeficiency virus (HIV-1/HTLV-IIIBa-L) replication in fresh and cultured human peripheral blood monocytes/macrophages by azidothymidine and related 2',3'-dideoxynucleosides.
Perno CF; Yarchoan R; Cooney DA; Hartman NR; Gartner S; Popovic M; Hao Z; Gerrard TL; Wilson YA; Johns DG
J Exp Med; 1988 Sep; 168(3):1111-25. PubMed ID: 2844951
[TBL] [Abstract][Full Text] [Related]
18. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.
Baba M; Shigeta S; Yuasa S; Takashima H; Sekiya K; Ubasawa M; Tanaka H; Miyasaka T; Walker RT; De Clercq E
Antimicrob Agents Chemother; 1994 Apr; 38(4):688-92. PubMed ID: 7518216
[TBL] [Abstract][Full Text] [Related]
19. Selective inhibition of human immunodeficiency virus type 1 replication by novel fluoroalkylated oligomers in vitro.
Baba M; Kira T; Shigeta S; Matsumoto T; Sawada H
J Acquir Immune Defic Syndr (1988); 1994 Jan; 7(1):24-30. PubMed ID: 8263750
[TBL] [Abstract][Full Text] [Related]
20. Suppression of HIV production in resting lymphocytes by combining didanosine and hydroxamate compounds.
Malley SD; Grange JM; Hamedi-Sangsari F; Vila JR
Lancet; 1994 May; 343(8908):1292. PubMed ID: 7910296
[No Abstract] [Full Text] [Related]
[Next] [New Search]
